1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

World First Clinical Trial Supports Use of Kava to Treat Anxiety

By Dr.Evil, May 13, 2013 | Updated: May 21, 2013 | | |
Tags:
  1. Dr.Evil
    May 13, 2013 — A world-first completed clinical study by an Australian team has found Kava, a medicinal South Pacific plant, significantly reduced the symptoms of people suffering anxiety.

    The study, led by the University of Melbourne and published in the Journal of Clinical Psychopharmacology, revealed Kava could be an alternative treatment to pharmaceutical products for the hundreds of thousands of Australians who suffer from Generalised Anxiety Disorders (GAD)
    Lead researcher, Dr Jerome Sarris from Department of Psychiatry at the University of Melbourne, said GAD is a complex condition that significantly affected people's day-today lives. Existing medications have a modest clinical effect and new effective options were needed for patients with anxiety. "Based on previous work we have recognised that plant based medicines may be a viable treatment for patients with chronic anxiety. In this study we've been able to show that Kava offers a potential natural alternative for the treatment of chronic clinical anxiety. Unlike some other options it has less risk of dependency and less potential for side effects," he said.

    The study also found that people's genetic differences (polymorphisms) of certain neurobiological mechanisms called GABA transporters, may modify their response to Kava. "If this finding is replicated, it may pave the way for simple genetic tests to determine which people may be likely to have a beneficial anxiety-reducing effect from taking Kava," Dr Sarris said.

    During the eight-week study, 75 patients with clinically diagnosed Generalised Anxiety Disorder were given Kava or placebo, and anxiety levels were regularly assessed. Results showed a significant reduction in anxiety for the Kava group compared to the placebo group at the end of the study.
    In participants diagnosed with moderate to severe GAD, Kava had an even greater effect in reducing anxiety. Following the completion of the controlled phase, 26 per cent of the Kava group were classified as in remission from their symptoms compared to six per cent of the placebo group.

    Participants in the Kava group were given tablets twice per day consisting of water-soluble extracted Kava (peeled rootstock) for a total dose of 120mg of kavalactones for the first three-week controlled phase. In cases of non-response this was increased to a double-dose twice per day for the second three-week controlled phase. Participants in the placebo group took matching dummy tablets in the same manner.
    Kava was also well tolerated. Results showed no significant differences across the two groups for liver function which had previously been a concern for Kava's medicinal use. In addition there were no considerable adverse reactions that could be attributed to Kava and no difference in withdrawal or addiction between the groups.
    An additional novel finding of the study, recently published in Phytotherapy Research was that Kava increased women's sex drive compared to those in the placebo group, believed to be due to the reduction of anxiety, rather than any aphrodisiac effect.

    Future studies confirming the genetic relationship to therapeutic response, and any libido-improving effects from Kava is now required. Dr Sarris said these significant findings are of importance to sufferers of anxiety and to the South Pacific region which relies on Kava as a major export.
    The study was funded by the NHMRC and Integria Healthcare who manufacture MediHerb and Thompson's Kava products.

    Source

    Edit: So I did read the rules for posting, only one I saw that I didn't do was bold the intro paragraph. Is there other formatting that is "customary" but not within the rules for posting??

Comments

  1. torachi
    Hey Dr Evil,

    You almost got it, its real easy. You got the title right. The very next thing should be the first paragraph of the article, bolded like you did. Then the articles paragraphs with a space between each. Then if provided, the date it was published and the articles author. The post should conclude with the source at the bottom.

    So basically take the date and source at the top and put them at the bottom. Hope this helps...keep posting news!
To make a comment simply sign up and become a member!